PsychedelicNewsBreaks

TuesdayOct 12, 2021 11:59 am

PsychedelicNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Duncan Trussell to Keynote at Meet Delic: The World’s Premiere Psychedelic and Wellness Event

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, today announced that Duncan Trussell will serve as a keynote speaker at Meet Delic on Nov. 6, 2021. An actor and stand-up comedian, Trussell co-created and appears in the Netflix animated series “The Midnight Gospel” and regularly travels the country performing comedy at festivals and shows. He also hosts the “Duncan Trussell Family Hour” podcast. Meet Delic is the largest and most comprehensive event to learn about the intersection of psychedelics, wellness and business with like-minded visionaries. Trussell's keynote will be a live taping of his podcast,…

Continue Reading

TuesdayOct 12, 2021 11:28 am

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present at KSCA Psychedelics Virtual Investor Conference

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that it will present at the KCSA Psychedelics Virtual Investor Conference at 3:00 p.m. ET on Oct. 14, 2021. The event is slated to take place virtually on Oct. 13-14, 2021. Tryp’s Chief Financial Officer Luke Hayes will provide a live overview of the company's activities and elaborate on how Tryp is leading the next wave of psychedelic drug development beyond mental health with its focus on chronic pain and other indications. Interested parties should visit https://ibn.fm/1Y2RX to…

Continue Reading

TuesdayOct 12, 2021 10:48 am

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Files International Patent Application in Continued Expansion of IP Portfolio

Cybin (NYSE American: CYBN) (NEO: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, announced that it has filed an international patent application related to methods for the delivery of psychedelic medications by inhalation and devices for performing those methods. According to the update, the application, governed by the Patent Cooperation Treaty (“PCT”), brings the potential to obtain patent coverage in 153 countries. “The continued progression of our research programs guides our discovery of new molecules and differentiating treatment approaches,” said Doug Drysdale, the company’s CEO. “Continued innovation, as demonstrated by our expanding IP portfolio, positions Cybin as a leading…

Continue Reading

MondayOct 11, 2021 1:42 pm

PsychedelicNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Stands Distinct in World of Cancer Prevention, Treatment

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, is a proven early thought leader and developer of multi-cancer (also called pan-cancer) ideas and technology. “AnPac Bio is one of the first companies in the world to produce major theories and methods of multi-level, multi-parameter and multi-cancer screening. The innovative technology has opened up a new field in early cancer screening that is based on a biophysical property and has achieved significant results,” reads a recent article. AnPac Bio has one of the largest sample libraries in the world, with more than 220,000 samples…

Continue Reading

MondayOct 11, 2021 1:27 pm

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Preparing for Clinical Trials Amid Growing Push for New Federally Approved Therapeutic

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) expects to soon launch a phase 2a clinical trial to determine the efficacy of its psychedelic drug candidate TRP-8802 in treating Prader-Willi Syndrome, hypothalamic obesity eating disorder resulting from removal of a brain tumor, and binge eating disorder. According to a recent article, TRP-8802 will be used in combination with psychotherapy under professional care to create the proper mindset for the neuroplasticity benefits of psilocybin to take full effect. Tryp then plans to proceed into phase 2b clinical trials with drug candidate TRP-8803 to test the trademarked product’s ability to penetrate the natural blood-brain…

Continue Reading

MondayOct 11, 2021 1:09 pm

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Poised Amid New Research Surrounding Psilocybin

Cybin (NEO: CYBN) (NYSE American: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, is likely to benefit from new research touting psilocybin mental health treatments. According to recent news from a group of Yale researchers, psilocybin has been found to counteract symptoms of depression (https://ibn.fm/NCORl). “Yale researchers found that a single dose of the naturally occurring psychedelic compound psilocybin can cause structural changes in the brain that counteract symptoms of depression,” reads a recent article quoting a Yale Daily News publication titled “Yale Researchers Discover Healing Effects of Psychedelic Drug.” In the piece published…

Continue Reading

ThursdayOct 07, 2021 2:12 pm

PsychedelicNewsBreaks – Clearmind Medicine Inc. (CSE: CMND) Engages Clinipace in Pursuit of FDA Approval for Therapeutics

Clearmind Medicine (CSE: CMND), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, today announced a strategic partnership. Clearmind has engaged Clinipace Incorporated, a full-service contract research organization (“CRO”), to advise the company in its pursuit of Food and Drug Administration (“FDA”) approval for its therapeutics. “Moving any drug through the FDA approval process requires deep expertise and meticulous attention to detail; this is particularly true for psychedelics,” said Adi Zuloff-Shani, PhD., CEO of Clearmind. “We chose Clinipace as our CRO as they have facilitated dozens of…

Continue Reading

ThursdayOct 07, 2021 12:31 pm

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Collaboration with University of Wisconsin Researchers to Evaluate TRP-8803

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, this morning announced a collaboration to support clinical pharmacology studies for Tryp’s proprietary drug product TRP-8803. Dr. Paul Hutson, Professor of the Pharmacy Practice Division at the University of Wisconsin-Madison School of Pharmacy and Dr. Christopher Nicholas, Assistant Professor at the University of Wisconsin School of Medicine, will serve as investigators on the clinical pharmacology studies to assess the pharmacokinetics and safety of TRP-8803 in healthy, volunteer patients. The completion of the studies is anticipated to deliver additional regulatory support…

Continue Reading

WednesdayOct 06, 2021 10:53 am

PsychedelicNewsBreaks – Delic Holdings Inc.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Delic Labs Moves Forward with Strategic Steps toward Commercialization

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, has announced that Delic Labs, which is part of the Delic Corp. family, has applied for a Health Canada 56 Research Exemption. Approval of the application allows Delic Labs scientists to perform research and tests on compounds in addition to psychedelic mushrooms, which it currently holds a 56 research exemption to study. The new application would allow the lab to study substances such as MDMA and LSD. The lab has also submitted an application for a dealer’s license. These steps are part of a strategic plan leading toward…

Continue Reading

TuesdayOct 05, 2021 10:01 am

PsychedelicNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Names Keynote Speaker for Upcoming Premiere Psychedelic and Wellness Event

Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, has announced the keynote speaker for its upcoming Meet Delic event, a revolutionary, two-day immersive edutainment experience designed to bring together the world's leading psychedelic and wellness thought and business leaders. Dr. Molly Maloof, MD, will speak at the premiere event, which will take place on Nov. 6, 2021. Maloof has an impressive background of working with investors, entrepreneurs, and executives to optimize their health. She has also consulted with an estimated 45 companies that operate in the digital health, consumer health and biotechnology industries. Cofounder of the…

Continue Reading